Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Applied DNA Sciences, Inc. APDN NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
24/100
0/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.50
-73.3%

Applied DNA Sciences, Inc. (APDN) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $5.62. It has a SharesGrow Score of 24/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is APDN = $2 (-73.3% upside).

Financials: revenue is $2M, -46.2%/yr average growth. Net income is $69M (loss), growing at -294.3%/yr. Net profit margin is -3251.7% (negative). Gross margin is 39.3% (+11.5 pp trend).

Balance sheet: total debt is $193,250 against $2M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 0.91 (tight liquidity). Debt-to-assets is 4.4%. Total assets: $4M.

Analyst outlook: 3 / 4 analysts rate APDN as buy (75%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 36/100 (Fail), Future 49/100 (Partial), Income 10/100 (Fail).

$1.50
▼ 73.31% Downside
Average Price Target
The 12-month price target for Applied DNA Sciences, Inc. is $1.50.

APDN SharesGrow Score Overview

28/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 36/100
Gross margin is + market cap
FUTURE 49/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — APDN

✗
VALUE Fail
10/100
APDN trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $2, implying -64.4% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
APDN: -46.2%/yr revenue is, -294.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet APDN: Debt-to-Equity (D/E) ratio 0.1 (conservative), Current ratio is 0.91 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
36/100
APDN: Gross margin is 39.3% (+11.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 36/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
49/100
Analyst outlook: 3 / 4 analysts rate APDN as buy (75%). Analyst consensus target is $2 (-64.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
APDN: Net profit margin is -3251.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.13-319.95
Volume2.65M
Avg Volume (30D)469.22K
Market Cap$7.26M
Beta (1Y)0.13
Share Statistics
EPS (TTM)-134.23
Shares Outstanding$517.67K
IPO Date2003-07-15
Employees46
CEOJames A. Hayward Sc.D.
Financial Highlights & Ratios
Revenue (TTM)$2.14M
Gross Profit$838.91K
EBITDA$-16.05M
Net Income$-69.49M
Operating Income$-16.05M
Total Cash$1.67M
Total Debt$193.25K
Net Debt$-1.47M
Total Assets$4.44M
Price / Earnings (P/E)-0
Price / Sales (P/S)3.4
Analyst Forecast
1Y Price Target$1.50
Target High$1.50
Target Low$1.50
Upside-73.3%
Rating ConsensusBuy
Analysts Covering4
Buy 75% Hold 0% Sell 25%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS03815U6073

Price Chart

Track all markets on TradingView
APDN
Applied DNA Sciences, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Diagnostics & Research
2.13 52WK RANGE 319.95

People Also View

OLK
OLK
Olink Holding AB (publ)
$26.08
+0.31%
 PSNL
PSNL
Personalis, Inc.
$6.68
+5.86%
 PRE
PRE
Prenetics Global Limited
$18.01
-0.88%
 GTH
GTH
Genetron Holdings Limited
$4.03
+0.12%
 FONR
FONR
FONAR Corporation
$18.76
+0.27%
 STIM
STIM
Neuronetics, Inc.
$1.43
+2.88%
 BDSX
BDSX
Biodesix, Inc.
$12.14
-9.13%
 OCX
OCX
OncoCyte Corporation
$3.20
+17.22%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message